BPC-157

BPC-157 is a stable 15–amino-acid sequence originally isolated from a protein found in human gastric juice. In animal models it appears to accelerate healing by promoting vascular recruitment and soft-tissue repair, and by supporting cell survival and migration in tendon and gut tissue. These effects have been consistently observed in rodent models, but the precise mechanisms remain under investigation and have not been confirmed in humans.

The BPC-157 literature is large but almost exclusively preclinical: hundreds of rodent studies report faster healing of tendon, muscle, ligament, bone, and gut tissue, often from a single research group. There are, as of this writing, no published randomized controlled trials in humans. That gap is the single most important fact about this compound — strong animal signals do not guarantee human benefit or safety, and the absence of long-term human safety data is a real limitation, not a footnote.

• Accelerated tendon and ligament healing in rat injury models
• Faster muscle and bone healing after experimental injury
• Protection and healing of the GI tract in models of ulcer and inflammatory bowel disease
• Counteracting NSAID-induced gut damage in animals

• No published human RCTs — efficacy in people is unproven
• No long-term human safety data; effects of chronic dosing are unknown
• Sold "for research use only," so purity, dose accuracy, and contamination vary by source
• Theoretical concern that pro-angiogenic activity could be undesirable in people with cancer
• Not approved by the FDA for any human use

Research compound. Sold "for research use only" — not approved for human consumption.

Goals studied: Tendon & ligament repair, Gut healing, Muscle recovery

Is BPC-157 proven to work in humans?

No. The evidence base is overwhelmingly animal studies. There are no published randomized controlled trials in humans, so human efficacy is unproven.

Is BPC-157 legal?

In the US it is sold only as a "research compound," not approved for human use. In 2023 the FDA flagged it for removal from the list of bulk substances compounding pharmacies may use. It is also banned in sport by WADA.

How is BPC-157 taken in studies?

Animal studies use both injection and oral administration. Because there are no human dosing trials, any human "protocol" circulating online is extrapolated from rodent data, not established.

1. [1]
   Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing

   Gwyer D, Wragg NM, Wilson SL · Cell and Tissue Research · 2019 · PMID 30915550 · model: animal

   Revue de la littérature préclinique concluant que le BPC-157 accélère la réparation des tendons, ligaments et muscles dans divers modèles de lésion.

2. [2]
   The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

   Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS · Journal of Applied Physiology · 2011 · PMID 21030672 · model: in-vitro

   Étude cellulaire reliant le BPC-157 à la croissance, la survie et la migration des ténocytes via la voie FAK-paxilline.

3. [3]
   Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing

   Sikiric P, et al. · Current Pharmaceutical Design · 2018 · PMID 29879879 · model: animal

   Revue situant les effets gastro-protecteurs et vasculaires du BPC-157 dans les modèles précliniques autour de l'angiogenèse.